Background: CT-P6 is a proposed biosimilar to reference trastuzumab. In this study, we aimed to establish equivalence of CT-P6 to reference trastuzumab in neoadjuvant treatment of HER2-positive early-stage breast cancer.

Book Title: CT-P6 Compared with Reference Trastuzumab for HER2-positive Breast Cancer: a Randomised, Double-blind, Active-controlled, Phase 3 Equivalence Trial
Author:
Published on 2017 by
ISBN: /
Total Page:
Book Category:
Book is About: Breast Cancer Treatment
Get CT-P6 Compared with Reference Trastuzumab for HER2-positive Breast Cancer: a Randomised, Double-blind, Active-controlled, Phase 3 Equivalence Trial eBook


Get the Ebook

Background: CT-P6 is a proposed biosimilar to reference trastuzumab. In this study, we aimed to establish equivalence of CT-P6 to reference trastuzumab in neoadjuvant treatment of HER2-positive early-stage breast cancer. Methods: In this randomised, double-blind, active-controlled, phase 3 equivalence trial, we recruited women aged 18 years or older with stage I–IIIa operable HER2-positive breast cancer from 112 centres in 23 countries. Inclusion criteria were an Eastern Cooperative Oncology Group performance status score of 0 or 1; a normal left ventricular ejection fraction of at least 55%; adequate bone marrow, hepatic, and renal function; at least one measureable lesion; and known oestrogen and progesterone receptor status. Exclusion criteria included bilateral breast cancer, previous breast cancer treatment, previous anthracycline treatment, and pregnancy or lactation. We randomly allocated patients 1:1 to receive neoadjuvant CT-P6 or reference trastuzumab intravenously (eight cycles, each lasting 3 weeks, for 24 weeks; 8 mg/kg on day 1 of cycle 1 and 6 mg/kg on day 1 of cycles 2–8) in conjunction with neoadjuvant docetaxel (75 mg/m 2 on day 1 of cycles 1–4) and FEC (fluorouracil [500 mg/m 2 ], epirubicin [75 mg/m 2 ], and cyclophosphamide [500 mg/m 2 ]; day 1 of cycles 5–8) therapy. We stratified randomisation by clinical stage, receptor status, and country and used permuted blocks. We did surgery within 3–6 weeks of the final neoadjuvant study drug dose, followed by an adjuvant treatment period of up to 1 year. We monitored long-term safety and efficacy for 3 years after the last patient was enrolled. Participants and investigators were masked to treatment until study completion. The primary efficacy endpoint, analysed in the per-protocol population, was pathological complete response, assessed via specimens obtained during surgery, analysed by masked central review of local histopathology reports. The equivalence margin was −0·15 to 0·15. This trial is registered withClinicalTrials.gov, numberNCT02162667, and is ongoing, but no longer recruiting. Findings: Between Aug 7, 2014, and May 6, 2016, we randomly allocated 549 patients (271 [49%] to CT-P6 vs 278 [51%] to reference trastuzumab). A similar proportion of patients achieved pathological complete response with CT-P6 (116 [46·8%; 95% CI 40·4–53·2] of 248 patients) and reference trastuzumab (129 [50·4%; 44·1–56·7] of 256 patients). The 95% CI of the estimated treatment outcome difference (−0·04% [95% CI −0·12 to 0·05]) was within the equivalence margin. 19 (7%) of 271 patients in the CT-P6 group reported serious treatment-emergent adverse events versus 22 (8%) of 278 in the reference trastuzumab group; frequent (occurring in more than one patient) serious adverse events were febrile neutropenia (four [1%] vs one [

From the most popular Breast Cancer Treatment Books, CT-P6 Compared with Reference Trastuzumab for HER2-positive Breast Cancer: a Randomised, Double-blind, Active-controlled, Phase 3 Equivalence Trial is the one of great book to have. You can get ebook from:

There are so many ebooks about CT-P6 Compared with Reference Trastuzumab for HER2-positive Breast Cancer: a Randomised, Double-blind, Active-controlled, Phase 3 Equivalence Trial that are available to have. Thinking of having CT-P6 Compared with Reference Trastuzumab for HER2-positive Breast Cancer: a Randomised, Double-blind, Active-controlled, Phase 3 Equivalence Trial ebook? You are in the right place. Get the ebook CT-P6 Compared with Reference Trastuzumab for HER2-positive Breast Cancer: a Randomised, Double-blind, Active-controlled, Phase 3 Equivalence Trial by: .

Ebook entitled: CT-P6 Compared with Reference Trastuzumab for HER2-positive Breast Cancer: a Randomised, Double-blind, Active-controlled, Phase 3 Equivalence Trial

Get the Ebooks

Book Details:
  1. Book was ranked at 32 by Google Books for CT-P6 Compared with Reference Trastuzumab for HER2-positive Breast Cancer: a Randomised, Double-blind, Active-controlled, Phase 3 Equivalence Trial
  2. CT-P6 Compared with Reference Trastuzumab for HER2-positive Breast Cancer: a Randomised, Double-blind, Active-controlled, Phase 3 Equivalence Trial published by since 2017 with ISBNs. The book ISBN 13 Code is and ISBN 10 Code is
  3. Reading Mode in Text Status is false and Reading Mode in Image Status is false
  4. The book has " Pages" is Printed at BOOK under Category
  5. Rated by Raters and have average rate at ""
  6. eBook Maturity (Adult Book) status is NOT_MATURE
  7. eBook written in en
  8. Book Preview Address: http://books.google.com/books?id=lZ7AvQEACAAJ&dq=Breast+Cancer+Treatment&hl=&cd=351&source=gbs_api

Book Preview


Get Ebooks

The Button is not working? Try The Alternative links for "CT-P6 Compared with Reference Trastuzumab for HER2-positive Breast Cancer: a Randomised, Double-blind, Active-controlled, Phase 3 Equivalence Trial by: ":